Abstract:

【Abstract】 Objective To explore the effectiveness of chlormadinone acetate in the treatment of patients with benign prostatic hyperplasia. Methods Thirty-two patients with benign prostatic hyperplasia were included in the study. All patients received chlormadinone acetate (50 mg/d) for 18 weeks. The prostate volume, International Prostate Symptom Score/Quality of Life,(IPSS/QoL), maximum urinary flow rate, international index of erectile function-5 (IIEF-5), and the adverse events were recorded. Results After treatment with chlormadinone acetate, the IPSS, IPSS voiding score, IPSS storage score, QoL, and IIEF-5 significantly decreased in patients(P<0.05). Meanwhile, maximum urinary flow rate significantly increased (P<0.05). Conclusion The therapy with chlormadinone acetate effectively relieves the symptoms of benign prostatic hyperplasia and improves the quality of life.

Key words: Benign prostatic hyperplasia (BPH), Chlormadinone acetate

摘要： 【摘要】目的 探讨醋酸氯地孕酮治疗良性前列腺增生的临床疗效。方法 观察32例接受醋酸氯地孕酮(CMA)治疗的良性前列腺增生患者(50 mg/d, qd),治疗18周后,对比分析治疗前后前列腺体积、国际前列腺症状评分/生活质量评分(IPSS/QoL)、最大尿流率、勃起功能国际问卷(IIEF-5),并记录出现的不良事件。结果 用药18周后,患者前列腺体积、IPSS、PSS?鄄排尿期症状评分、IPSS-储尿期症状评分、生活质量评分、IIEF-5均较治疗前均明显下降(P<0.05);最大尿流率较治疗前均明显上升(P<0.05)。结论 醋酸氯地孕酮可较全面地缓解良性前列腺增生患者的症状,有利于患者生活质量的改善。

关键词: 良性前列腺增生, 醋酸氯地孕酮